Neurocrine Biosciences
NBIX
#1574
Rank
S$16.60 B
Marketcap
S$165.41
Share price
-3.10%
Change (1 day)
11.39%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): S$6.19

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is S$6.21. an increase over its 2024 EPS that were of S$4.36.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025S$6.0137.87%
2024S$4.3633.07%
2023S$3.2757.76%
2022S$2.0869.47%
2021S$1.22-78.21%
2020S$5.62990%
2019S$0.5281.82%
2018S$0.28-113.5%
2017S-$2.100.62%
2016S-$2.0957.28%
2015S-$1.3325.61%
2014S-$1.0618.84%
2013S-$0.89-1085.71%
2012S$0.09024

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
S$1.75-71.78%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$3.08-50.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$29.68 377.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S$1.12-81.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S-$2.62-142.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$2.20-64.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
S-$38.54-720.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.26-63.56%๐Ÿ‡ฌ๐Ÿ‡ง UK